Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 clients • 9 examiners • 9 art units • 0 of 10 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Law Offices of Alan J. Morrison has 10 pending office actions in Biotechnology & Pharmaceuticals and 106 career applications. The profile shows an active current workload relative to its supplied historical application record in this technology area.
The resolved allowance rate is 72.73%, and the average is 5.33 office actions per allowance. The rate records resolved allowance outcomes, while the average indicates more extensive examination activity associated with allowed matters. Practitioners should account for potentially repeated prosecution exchanges when planning responses, while treating these historical measures as context rather than as a forecast for current applications.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 4 (40%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 1 (10%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHUPE, ELIZABETH A | 2 | 65.8% | +45.5% |
| DRISCOLL, LORA E BARNHART | 1 | 31.8% | +20.8% |
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| NICOL, ALEXANDER W | 1 | 42.7% | +43.6% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| BARRERA, IMMACULADA | 1 | 30.0% | +80.8% |
| AL-AWADI, DANAH J | 1 | 54.6% | +13.2% |
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295893 | Synchronized Cell-Based Compositions | MYERS, CARLA J | 26d overdue |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 18d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | MITCHELL, EDWIN COLEMAN | 139d overdue |
| 18062642 | Lymphocyte-Based PKCe Test for Alzheimer's Disease | NICOL, ALEXANDER W | 105d overdue |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 79d overdue |
| 18295893 | Synchronized Cell-Based Compositions | MYERS, CARLA J | 26d overdue |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 18d overdue |
| 18698856 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 29d |
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | AL-AWADI, DANAH J | 39d |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | SAOUD, CHRISTINE J | 75d |
| Client (Assignee) | Pending OAs |
|---|---|
| Maddon Advisors LLC | 4 |
| Biovena Science, LLC | 2 |
| Rowan University | 1 |
| NeuroGX LLC | 1 |
| NeuroDiagnostics LLC | 1 |
| Babak Behnam | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 3991 | 1 |
| 1682 | 1 |
| 1645 | 1 |
| 1634 | 1 |
| 1626 | 1 |
| 1671 | 1 |
| 1615 | 1 |
| 1619 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18825927 | DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES | Rowan University | DRISCOLL, LORA E BARNHART | 3991 | §112DPOther | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18698856 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Maddon Advisors LLC | SHUPE, ELIZABETH A | 1643 | §103§112DP | Final Rejection | 29d | Pending | Apr 05, 2024 |
| 18295893 | Synchronized Cell-Based Compositions | Neurogx LLC | MYERS, CARLA J | 1682 | §101§102§103 | Final Rejection | 26d overdue | Pending | Apr 05, 2023 |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | Maddon Advisors LLC | SAOUD, CHRISTINE J | 1645 | §103Other | Non-Final OA | 75d | Pending | Dec 16, 2022 |
| 18062642 | Lymphocyte-Based PKCe Test for Alzheimer's Disease | Neurodiagnostics LLC | NICOL, ALEXANDER W | 1634 | — | Final Rejection | 105d overdue | Pending | Dec 07, 2022 |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | Babak Behnam | FETTEROLF, BRANDON J | 1626 | §102§103 | Non-Final OA | 18d overdue | Pending | Nov 21, 2022 |
| 17996019 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Maddon Advisors LLC | BARRERA, IMMACULADA | 1671 | §103Other | Final Rejection | — | Pending | Oct 12, 2022 |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Maddon Advisors LLC | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | 79d overdue | Pending | Oct 12, 2021 |
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | Biovena Science, LLC | AL-AWADI, DANAH J | 1615 | §103 | Final Rejection | 39d | Pending | Mar 18, 2021 |
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | Biovena Science, LLC | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 139d overdue | Pending | Mar 18, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial72.7% of resolved applications prosecuted by Law Offices Of Alan J. Morrison were allowed, across 106 applications in USPTO records.
5.33 office actions per allowed application on average.
10 pending office actions as of October 2026, for 6 clients, before 9 examiners in 9 art units.
